Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Minocycline Topical Clear all
Completed Phase 3 Interventional Results available

Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis

NCT00529555
View directory record Official record
Conditions
Adult Periodontitis
Interventions
minocycline HCl 2.1%, Scaling and root planing
Drug · Procedure
Lead sponsor
Sunstar Americas
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Gainsville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 14, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional Results available

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

NCT01349192
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Rifampin, Trimethoprim/Sulfamethoxazole, Minocycline, Mupirocin, chlorhexidine gluconate oral rinse, 2% Chlorhexidine solution wipes, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Birmingham, Alabama • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

NCT02946788
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Minocycline
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Coral Gables, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815267
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Birmingham, Alabama • Fremont, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

NCT02709096
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BPX-01, 1% Topical Gel, BPX-01 Vehicle Gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lipids of the Human Tear Film and Their Effect on Tear Stability

NCT00803452
View directory record Official record
Conditions
Blepharitis
Interventions
doxycycline, azithromycin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

NCT03271021
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
1,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
98
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 14, 2026, 8:41 PM EDT
Not listed Phase 2 Interventional

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

NCT03667222
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
minocycline topical gel, topical gel vehicle
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Anaheim Hills, California • Miami, Florida • Miramar, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 14, 2026, 8:41 PM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 14, 2026, 8:41 PM EDT
Completed No phase listed Observational

Topical Antisepsis in Head and Neck Cancer Surgery

NCT04721626
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Chlorhexidine Gluconate, Povidone-iodine, Tetracycline Ointment
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin, Chlorhexidine Gluconate, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
2 Years to 45 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

NCT01874860
View directory record Official record
Conditions
Colorectal Cancer, Head and Neck Cancer
Interventions
Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid)
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

NCT03888378
View directory record Official record
Conditions
Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction
Interventions
0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Azusa, California • Huntington Beach, California • Inglewood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

NCT04104685
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam
Combination Product · Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 14, 2026, 8:41 PM EDT
Recruiting Early Phase 1 Interventional

Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics

NCT07298057
View directory record Official record
Conditions
Periodontitis, Diabetes Mellitus Type 2
Interventions
local antibiotic application of topical minocycline, Scaling and Root Planing
Drug · Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 4 Interventional

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

NCT04940767
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin, Amzeeq 4% Topical Foam
Drug
Lead sponsor
Edward Lain, MD
Network
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Dripping Springs, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
FMX103 1.5%
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
79
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815280
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Glendale, Arizona • Rogers, Arkansas • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

NCT01931150
View directory record Official record
Conditions
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Interventions
Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

NCT02815332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BPX-01 1% Minocycline Topical Gel, BPX-01 2% Minocycline Topical Gel, BPX-01 Vehicle Topical Gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
9 Years to 40 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Santa Monica, California • Coral Gables, Florida • Lake Mary, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 14, 2026, 8:41 PM EDT
Not listed Phase 2 Interventional

Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline

NCT04202263
View directory record Official record
Conditions
Allergic Rhinitis, Asthma
Interventions
Minocycline Topical, Placebos
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

NCT03263273
View directory record Official record
Conditions
Rosacea, Papulopustular Rosacea
Interventions
1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
23
States / cities
Bryant, Arkansas • Rogers, Arkansas • Fremont, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 14, 2026, 8:41 PM EDT
Completed Phase 3 Interventional Results available

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT03142451
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 14, 2026, 8:41 PM EDT